An interventional study of ARCHITECT applicator in Locally Advanced Cervical Cancer and Uterine Carcinoma, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Uterine Cervical Neoplasms with a site in Netherlands — 15 open to participants now, 18 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Netherlands.
Among the 53 studies in Uterine Cervical Neoplasms with a site in Netherlands, this one is the 33rd largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2026, is one of 9 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 51st registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →15 of the 53 studies in Uterine Cervical Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Netherlands
Ages 18+ · Women only
University Medical Center Groningen · Sites in Netherlands
Ages 18+ · Women only
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18+
Daiichi Sankyo · Sites in Netherlands, United States, Argentina and 15 more countries
Ages 18+
Daiichi Sankyo · Sites in Netherlands, United States, Australia and 13 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 16 · Phase 3 7 · Phase 4 1
First in 1996; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 214 across the 41 interventional studies, 84 across the 11 observational. Of the 30 that completed or were terminated, 10 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 53 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 2 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Uterine Cervical Neoplasms with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05527184AbbVieFirst in Human Study of IMGN151 in Recurrent Gynaecological Cancers | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Uterine Cervical Neoplasms with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, non-randomised, single centre, phase I trial assesses the clinical feasibility of the use of the patient-tailored ARCHITECT applicator in locally advanced cervical cancer brachytherapy.
Image-guided adaptive brachytherapy is an essential part of the standard treatment of locally advanced cervical cancer (LACC). During LACC brachytherapy, a radioactive source is guided through an applicator implanted in the vaginal and uterine cavity, as well as through interstitial needles near or inside the tumour tissue. However, in certain patient groups, current commercially available applicators cannot meet dose objectives. Alternative approaches are technically challenging and dependent on the clinician's experience.
In the ARCHITECT project, a single-use, 3D printed, patient-tailored applicator with optimised source channels is developed to overcome these limitations. The aim of this phase I study is to evaluate the clinical feasibility of the ARCHTECT applicator in brachytherapy for LACC.
Twenty-five patients with LACC will be treated with the standard treatment for LACC in concordance with the EMBRACE II protocol and (inter)national guidelines, including external beam radiation therapy (45 Gy in 25 fx with simultaneous integrated nodal boost in case of suspicion of lymph node metastases), concurrent weekly chemotherapy (cisplatin 40 mg/m2), and high-dose rate (HDR) image-guided adaptive brachytherapy (IGABT). HDR IGABT will be performed following the latest clinical guidelines, including 21-28 Gy in 3 to 4 fractions of 7 Gy, aiming for a total cumulative (EBRT+IGABT) dose of 90-95 Gy (EQD210 D90) to the high-risk-clinical target volume (CTV-THR). Deep hyperthermia in five sessions or no sensitizing therapy during EBRT is also allowed.
In general in Erasmus Medical Centre, two applications are applied with an interval of one week for the brachytherapy part. Patients will be treated with a commercially available applicator (conform the current clinical practice) at week 1 and with the patient-tailored ARCHITECT applicator (study intervention) at week 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In general in Erasmus Medical Centre, two applications are applied with an interval of one week for the HDR IGABT. Patients will be treated with a commercially available applicator (conform the current clinical practice) at week 1 and with the patient-tailored ARCHITECT applicator (study intervention) at week 2.
Device: ARCHITECT applicator
Patient-tailored, 3D-printed applicator
Clinical feasibility
To deliver brachytherapy using the patient-tailored, 3D printed ARCHITECT applicator \[yes/no\]
Time frame: At week 2 (ARCHITECT applicator)
Brachytherapy-related adverse events
Organ perforation, vaginal bleeding, and device-related infection according to the common terminology criteria for adverse events (CTCAE) version 5
Time frame: At week 1 (standard applicator) and week 2 (ARCHITECT applicator): based on imaging (organ perforation), <1 hour after applicator removal (vaginal bleeding), <1-2 weeks after removal from the patient (device-related infection)
Brachytherapy plan quality
Dosimetric parameters (according to EMBRACE II): High-Risk Clinical Target Volume D90, High-Risk Clinical Target Volume D98, Intermediate-Risk Clinical Target Volume D98, and bladder , rectum , sigmoid , and bowel D2cm3 \[Gy\]
Time frame: At week 1 (standard applicator) and week 2 (ARCHITECT applicator)
Brachytherapy implant geometry
Optimal geometry of applicator, i.e. number of needles and spacing between needles \[mm\]
Time frame: At week 1 (standard applicator) and week 2 (ARCHITECT applicator)
User experience
Questions on a scale of 1-5 where 1 indicates "strongly disagree" and 5 "strongly agree" on following the topics: easy to insert applicator, easy to connect applicator to tandem, easy to insert the needles in terms of force, easy to reach required depth with needles, easy to fixate the needles, applicator fits well, easy to remove applicator and needles, easy to reconstruct applicator or needles, applicator did not move, needles did not move, easy to connect and disconnect to after loader.
Time frame: At week 1 (standard applicator) and 2 (ARCHITECT applicator)
Time required for the workflow
Process steps evaluated on time: designing the applicator, processing at manufacturer, processing before use, in operating room, delineating targets and organs-at-risk, reconstructing, treatment planning, checking, treating, removing applicator \[hours:minutes\]
Time frame: At week 1 (standard applicator) and week 2 (ARCHITECT applicator)
Pain perceived by patient
Perceptions of pain will be assessed using the 11-point, Numeric Rating Scale (NRS-11), where 0 indicates "no pain" and 10 represents the "worst imaginable pain"
Time frame: At week 1 (standard applicator) and week 2 (ARCHITECT applicator): <1 hour before the patient arrives at operating room, after each MR or CT imaging, and after removal from the patient
Integrity of the patient-tailored applicator
The ARCHITECT applicator will be visually inspected to detect any signs of compromised integrity: breakage \[yes/no\], cracking \[yes/no\], deformation \[yes/no\], material loss \[yes/no\].
Time frame: At week 2 (ARCHITECT applicator): after removal from the patient
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.
Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 17 months is below that.
Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jul 2026, on Sep 25, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.